Restart Life Sciences Corp. (CSE:HEAL)

Restart Life Sciences Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	0.01
Revenue Growth (YoY)	-	-	-	-	59.51%
Cost of Revenue	-	-	-	0.01	0.01
Gross Profit	-	-	-	-0.01	0
Selling, General & Admin	0.59	0.86	1.4	1.58	0.63
Research & Development	0	0.07	0.12	0.86	0.05
Operating Expenses	0.63	1.21	1.85	2.8	1.58
Operating Income	-0.63	-1.21	-1.85	-2.8	-1.58
Interest & Investment Income	-	-	0	0	0
Currency Exchange Gain (Loss)	0.01	-	-	-	-
Other Non Operating Income (Expenses)	-0.03	-0.02	0.14	-0.04	-0.22
EBT Excluding Unusual Items	-0.65	-1.22	-1.71	-2.84	-1.8
Gain (Loss) on Sale of Investments	-0.14	-	-	0.02	-5.69
Gain (Loss) on Sale of Assets	0.63	-	-	-	-
Other Unusual Items	0.38	-	-0.76	0.13	-17.74
Pretax Income	0.22	-1.22	-2.47	-2.68	-25.23
Net Income	0.22	-1.22	-2.47	-2.68	-25.23
Net Income to Common	0.22	-1.22	-2.47	-2.68	-25.23
Shares Outstanding (Basic)	15	15	14	11	5
Shares Outstanding (Diluted)	16	15	14	11	5
Shares Change (YoY)	9.79%	7.47%	22.91%	117.20%	59.88%
EPS (Basic)	0.01	-0.08	-0.18	-0.24	-4.93
EPS (Diluted)	0.01	-0.08	-0.18	-0.24	-4.93
Free Cash Flow	-0.07	-0.28	-2.41	-1.95	-0.86
Free Cash Flow Per Share	-0.00	-0.02	-0.18	-0.17	-0.17
Gross Margin	-	-	-	-	15.07%
Operating Margin	-	-	-	-	-13782.54%
Profit Margin	-	-	-	-	-219950.23%
Free Cash Flow Margin	-	-	-	-	-7466.27%
EBITDA	-0.62	-1.2	-1.84	-2.8	-1.57
D&A For EBITDA	0	0	0	0	0.01
EBIT	-0.63	-1.21	-1.85	-2.8	-1.58

Updated Nov 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.